2021-05-05

BACK

Cell Therapy for HCC

Cell Therapy for Hepatocellular Carcinoma (HCC)

Currently, cancer remains the No. 1 cause of death globally. Traditional cancer treatments, such as surgery, chemotherapy, radiotherapy, or targeted therapy, are applied to treat  early or late stages of cancer, respectively. When the cancer recurs or when it is discovered at an advanced stage, the patient's malignant tumor may not respond to or is resistant to the abovementioned standard treatments. There’s nothing doctors can do if they do not have better weapons.

In recent years, customized autologous immune cell therapy for cancer patients have represented a breakthrough development in cancer treatment, and it is also a new direction for the world's future pharmaceutical manufacturing.

Customized training of autologous immune cell troops

In order to accelerate the research and development of cell therapy technology and cell therapy products, Chang Gung Memorial Hospital (CGMH) has established a high-standard cell preparation site and a Cell Therapy Center. In 2020, the center officially started offering immune cell therapy for hepatocellular carcinoma (liver cancer) and stem cell therapy for osteoarthritis (degenerative arthritis), and developed more diversified cell therapy solutions to provide patients with personalized and precision treatment options with low side effects. Customized preparation of patients' personalized immune cells can precisely attack tumors and reduce side effects.

Using such medical technology, CGMH will be able to implement autologous immune cell therapy to serve cancer patients for whom standard treatment has failed or have advanced cancers.Only top international hospitals or pharmaceutical companies are capable of developing methods similar to this technology. This technology is considered completely personalized, and is capable of precisely hitting cancer cells and searching for hidden cancer cells without harming normal cells.

The "New Antigen Amplification Autologous Immune Cell Therapy Technology" developed by the core laboratory first uses cancer tissue obtained from the surgery or biopsy of the patient to find the gene mutation points of the individual tumor of the cancer patient through next-generation gene sequencing. Then, the immune cell activation technology developed by CGMH years ago is used to screen and design personalized cancer precision vaccines, and to prepare and amplify the patient's autologous immune cells that are capable of identifying tumor specificity in the Handling Room of the Cell Therapy Center. The immune cell preparation is then transfused back into the patient to kill tumor cells, thereby achieving personalized precision medicine.

Immune cell therapy (dendritic cell therapy) for hepatocellular carcinoma (HCC)

Offering new treatment options for patients with stages I to III HCC who have failed standard treatments.Treatment methods: Sampling of liver cancer biopsy / collecting peripheral blood, preparing tumor antigens / isolating monocytes, culturing dendritic cells and transfusing back to the patient to treat liver cancer after passing the release criteria.

Treatment procedures: Collect blood → culture for 9 days per dose → inject intravenously once a week for 3 doses in total. If the tumor is partially under control while other parts continue to grow, tumor samples can be recollected and the patients will be given three more treatments.

After cell therapy is implemented, and with good practice standards and supervision, top biomedical experts will be able to create new leading medical technologies in this field, which can not only become cutting-edge medical treatments, but also benefit cancer patients and bring precise and effective treatments for incurable diseases.

※ Currently, CGMH can carry out the following projects: Dendritic cell therapy for HCC, adipose stem cell therapy for knee osteoarthritis

More information:

Knee Osteoarthritis Adipose Stem Cell Therapy

© Chang Gung Memorial Hospital. All Rights Reserved